Background and objectives Pre-existing hepatitis B virus (HBV) infection has been associated in inferior renal transplant outcomes. We examined outcomes of HBVϩ renal recipients in a more recent era with availability of oral anti-viral agents.
Introduction
Pre-existing hepatitis B virus (HBV) infection has been considered a relative contraindication to kidney transplant. The use of immunosuppressive drugs enhances viral replication, leading to acceleration of liver injury and progression to hepatocellular failure (1) . Moreover, HBV-associated GN may recur or develop de novo in the graft, reducing function or even ultimately inducing graft failure (2, 3) .
Earlier studies had reported an adverse impact of HBV on patient and graft survivals (4 -7) . However, in the last decade, introduction of effective oral anti-viral therapies for HBV with judicious use of immunosuppressive drugs in recipients with viral hepatitis have altered management of HBV-infected recipients (8) . Using the Organ Procurement Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database, we examined outcomes of HBV-infected kidney recipients in a recent era (2001 to 2007) compared with noninfected HBV recipients.
Materials and Methods

Study Population
A retrospective cohort study was conducted using data from OPTN/UNOS as of May 2009. Adults (Ͼ18 years old) who were primary renal graft recipients between 2001 and 2007 and had at least one follow-up visit reported to OPTN/UNOS were included. Recipients of multiorgan transplant and those with pretransplant hepatitis C virus (HCV) infection (defined as positive antibody to HCV) were excluded. A recipient was characterized as HBV infected (HBVϩ) when seropositivity for hepatitis B surface antigen (HbsAgϩve) was recorded on the transplant registration form. A total of 75,681 recipients were included in the study population: 1346 were HBVϩ and 74,335 were HBVϪ.
Statistical Analysis
Donor, recipient, and transplant characteristics, including immunosuppressive regimens at discharge, were compared. The Kruskal-Wallis test was used to detect significant differences in continuous variables.
The
2 test was used to compare categorical variables. Post-transplant complications including primary nonfunction, delayed graft function (DGF 1 , need dialysis in the first week after transplant; DGF 2 , combination of DGF 1 with cases of creatinine decline Ͻ25% or urine output Ͻ40 ml in the first 24 hours after transplantation), 1-year cumulative acute rejection rates, and occurrence of glomerular disease in the graft were examined. Univariate comparisons of hepatic failure after kidney transplant, and graft and patient survival were performed using the Kaplan-Meier product limits method, with differences compared by logrank test. Overall kidney graft survival was determined from date of transplantation until recipient death, kidney retransplantation, or return to dialysis. Hepatic failure was defined as either listing for or receipt of a liver transplant after prior kidney transplant or hepatic failure as the reported cause of death (primary, secondary, or tertiary). Patients were censored at the end of the study period (60 months). Potential confounding covariates examined on univariate analysis included donor (living/deceased, expanded criteria donor), recipient (age, gender, race, diabetes, hypertension, cardiovascular disease, cerebrovascular disease, body mass index, dialysis duration, and peak panel reactive antibody), and transplant (cold ischemia time, HLA mismatch, and immunosupression type) factors. Covariates with P Ͻ 0.1 were included in multivariate analyses. Multivariate estimates of hazards of hepatic failure, overall graft failure, death-censored graft failure, and patient mortality were calculated using stepwise Cox proportional hazards model. The results were expressed as hazard ratios (HRs) with 95% confidence intervals (CIs) and associated P value. All reported P values were twotailed, and P Ͻ 0.05 was considered significant. All analyses were conducted using STATA Statistical Software, Release 10 (StateCorp LP, College Station, TX).
Comparing Transplant Outcomes in Different Eras
To evaluate the impact of HBV infection on long-term graft survival in different transplant eras, we also compared outcomes of recipients transplanted in three consec- 
Results
Baseline Characteristics
The study population included 75,681 adults primary kidney recipients transplanted between 2001 and 2007, of whom 1346 were HBVϩ and 74,335 were HBVϪ. The median follow-up was 1098 days. Recipient, donor, and transplant baseline characters are shown in Table 1 . The HBVϩ group had a significantly higher proportion of younger (Ͻ40 years) and Asian recipients, donors with seropositivity for HBV core antibody (HBcAb), recipients with a longer pretransplant dialysis period, recipients with increased HLA mismatch, and recipients discharged more frequently on rapamycin for immune suppression compared with the HBVϪ group. The HBVϪ group had a higher percentage of white recipients. Overall, the HBVϪ group had higher body mass index, more recipients with diabetes as the cause of ESRD, an increased frequency of associated comorbidities (notably hypertension and cerebrovascular disease) received more organs from living donors, and were more frequently discharged on steroids. There were no significant differences in recipient gender or transplant factors, including peak panel reactive antibody Ͼ10%; extended criteria donor; and cold ischemia time.
Impact of Recipient HBV Infection on Outcomes in 2001 to 2007
Post transplant complications. The median length of hospitalization was 6 (4 to 8) and 6 (4 to 9) days (P ϭ 0.82); incidence of primary nonfunction was 1.0 and 1.2% (P ϭ 0.49); rate of DGF 1 was 24.8% and 29.3% (P Ͻ 0.001) in deceased donors; rate of DGF 2 was 47.4% and 49.9% (P Ͻ 0.14) in deceased donors; 1-year cumulative rejection rate was 12.2% and 10.3% (P ϭ 0.08); and recurrence of graft glomerular disease was 0.24% versus 0% (P ϭ 0.07) for HBVϪ and HBVϩ recipients, respectively.
Hepatic failure after kidney transplant. The proportion of recipients who developed hepatic failure is shown in Figure 1 . The HBVϩ group had a higher percentage of recipients with hepatic failure after kidney transplant during the follow-up period compared with the HBVϪ group (11 in 1346, 0.82% versus 113 in 74,335, 0.15%, P Ͻ 0.01). Of the recipients with liver failure, 9 (0.67%) HBVϩ and 61 (0.08%) HBVϪ (P Ͻ 0.01) were listed for liver transplant. Five (0.37%) HBVϩ and 36 (0.05%) HBVϪ (P Ͻ 0.01) received a liver transplant, and 3 (0.22%) HBVϩ and 49 (0.07%) HBVϪ (P ϭ 0.03) died of liver failure. The median time to development of liver failure was 629 days (231 to 850 days) and 857 days (309 to 1381 days) in HBVϩ and HBVϪ, respectively. The unadjusted cumulative incidence of hepatic failure after kidney transplant was significantly higher in the HBVϩ group compared with the HBVϪ group (at 12, 36, and 60 months: 0.32%, 0.85%, and 1.29% for HBVϩ and 0.04%, 0.13%, and 0.20% for HBVϪ; P Ͻ 0.0001). The unadjusted and adjusted HRs for hepatic failure after kidney transplant are shown in Table 2 . By multivariate Cox regression analysis, pretransplant HBV infection was associated with an increased risk for hepatic failure after kidney transplant in both living (adjusted HR ϭ 6.5, P Ͻ 0.01) and deceased (adjusted HR ϭ 6.21, P Ͻ 0.01) donor recipients. Among the 120 recipients with liver failure, HBV was implicated in 7 (63.6%) of the 11 HBVϩ recipients compared with 6 (5.3%) of the 113 HBVϪ recipients (P Ͻ 0.01).
Kidney graft survival. Kaplan-Meier survival curves for overall kidney graft survival according to the presence or absence of recipient HBV infection are shown in Figure 2A . There was no significant difference in overall graft survival between recipients with and without HBV infection. Kidney graft survival in HBVϩ recipients at 12, 36, and 60 months was 92.8%, 84.2%, and 74.9% and in HBVϪ recipients was 92.9%, 84.5%, and 75.1%, respectively (log-rank test, P ϭ 0.94). Multivariate Cox regression analysis confirmed that HBV infection was not associated with graft failure in living donor trans-plant (HR ϭ 0.90, P ϭ 0.57) or in deceased donor transplant (HR ϭ 1.10, P ϭ 0.52), as seen in Table 3 .
Kaplan-Meier survival curves for death-censored graft survival are shown in Figure 2B . There was no significant difference in death-censored graft survival between recipients with and without HBV infection (at 12, 36, and 60 months: 95.6%, 90.7%, and 85.2% for HBVϩ and 95.6%, 90.5%, and 84.9% for HBVϪ; log-rank test, P ϭ 0.94). By multivariate Cox regression analysis, recipient HBV infection was not significantly associated with death-censored graft failure in living donor transplant (HR ϭ 0.74, P ϭ 0.26) or deceased donor transplant (HR ϭ 1.06, P ϭ 0.61; Table 3 ).
Patient mortality. The Kaplan-Meier survival curves for patient survival according to the presence or absence of recipient HBV infection are shown in Figure 2C . There was no significant difference in patient survival between recipients with and without HBV infection (at 12, 36, and 60 months: 96.3%, 91.1%, and 85.3% for HBVϩ and 96.3%, 91.6%, and 85.6% for HBVϪ; logrank test, P ϭ 0.85). By multivariate Cox regression analysis, recipient HBV infection was not significantly associated with patient mortality in living (HR ϭ 0.98, P ϭ 0.93) and deceased (HR ϭ 1.09, P ϭ 0.42) donor transplant ( Table 3) .
Impact of HBV infection on transplant outcomes in earlier transplant eras. Table 4 shows outcomes as patient and graft survival and proportion of recipients that did not 
Discussion
There were two important findings in our study. First, in the most recent period (2001 to 2007), patient and kidney graft survival in HBVϩ recipients was comparable to HBVϪ recipients, and after adjusting for confounders, the risks for death and graft loss were not different between HBVϩ and HBVϪ recipients. This is in contrast to earlier eras in transplant, 1984 to 1997, when HBV infection was implicated in inferior patient and graft survivals. Second, the incidence of severe liver disease was higher in HBVϩ recipients, and after adjustment, risk for developing severe liver disease associated with HBVϩ was 5.5-and 5.2-fold higher in HBVϩ living and deceased donors recipients, respectively, compared with HBVϪ recipients.
In HBV infected organ transplant recipients the course of liver disease may be accelerated by therapeutic immunosuppression. Previous reports described an increase in HBV viral load after renal transplantation with progression of liver disease to overt hepatocellular failure (4 -6). Consistent with prior reports, we found an increased risk of developing liver disease in HBVϩ recipients, although overall patient survival was not inferior to that of recipients without HBV infection. The advent of lamivudine in the 1990s expanded treatment options for HBV-infected renal transplant recipients in whom IFN is contraindicated because of concerns about graft loss. Fabrizi et al. (10) , in a meta-analysis of clinical trials of lamivudine for the treatment of HBV-related liver disease in renal transplantation, observed that lamivudine reduced viremia (91% clearance of HBV DNA) and normalized alanine aminotransferase in 81% of recipients and may slow progression of liver disease after renal transplant. However, viral resistance to lamivudine is frequent and limits its long-term efficiency. Adevofir was subsequently approved by the FDA in September 2002 for the treatment of chronic HBV in adults, with evidence of active viral replication including those with lamivudine resistance. Newer drugs, entecavir and tenofovir, more potent anti-viral agents than lamivudine and adefovir, are now licensed to treat HBV infection (9) . Thus anti-viral therapy for HBV has become increasingly effective and potentially may prevent HBV-related hepatocellular failure in HBV-infected renal transplant recipients.
Fabrizi et al. (10) , in a meta-analysis of kidney transplant outcomes in HBVϩ recipients, concluded that these recipients are at increased risk for mortality and kidney graft failure compared with HBVϪ recipients. Data were based on results of six older observational studies: three from Europe (11-13), two from Asia (14, 15) , and one from South America (16) . In contrast, using a North American database of renal transplants from a more recent era, we found that patient and kidney survival was not diminished in HBV-infected recipients.
A potential explanation for the differences in our findings from the meta-analysis of Fabrizi et al. (10) is that the former included recipients transplanted between 1972 and 1999 compared with our recipients from 2001 to 2007. Lamivudine licensed for therapy of HBV in 1996 and subsequent anti-viral agents have contributed to better outcomes in HBV-infected recipients. Two reports have appeared on lamivudine therapy and survival outcomes in kidney transplant recipients. Chan et al. (14) described 12 HBsAgϩ recipients who received lamivudine preemptively, i.e., when a increase in HBV DNA levels with or without elevation in aminotransferase levels were detected, had similar renal allograft recipient survival compared with HBSAgϪ controls in contrast to their HBVinfected recipients transplanted before lamivudine was available. Ahn et al. (17) included transplants performed between 1979 and 2004 and found 10-year patient, graft, and death-censored graft survival were inferior in HBsAgϩve (n ϭ 66) compared with HBsAgϪve (n ϭ 1988) recipients. However, in 27 HBsAgϩve recipients who received lamivudine, 10-year patient overall and kidney death censored survivals were comparable with HBsAgϪve recipients. We also confirmed that outcomes of HBVϩ recipients have improved significantly in the last decade. We found that overall kidney and patient survival Potential risk factors in the univariate analysis with a P Ͻ 0.1 were selected to be included in the multivariate analysis. Other analyzed covariates: recipient gender, body mass index, race, comorbidity (diabetes, hypertension, cerebrovascular disease), dialysis duration, induction therapy, and immunosuppressants at discharge (tacrolimus, mycophenolate mofetil and enteric coated mycophenolate sodium, mammalian target of rapamycin inhibitors). Recipient age and cold ischemia time were not included in the multivariate model for living donor recipients because the P value in univariate analysis was Ͼ0.1. Expanded criteria donor was not included in the multivariate model for deceased donor recipients because the P value in univariate analysis was Ͼ0.1. HR, hazard ratio; CI, confidence interval.
plant HBVϩ recipients according to three eras: era 1 (1987 to 1991), era 2 (1992 to 1996), and era 3 (1997 to 2002) and showed that the survival of HBVϩ recipients was significantly better for era 2 than in era 1 and for era 3 than in era 2; also, there were no difference in survival between patients with HBVϩ and other diagnoses for era 3. These similar findings in kidney and liver transplants suggest an overall improvement in HBVϩ organ transplant recipient outcomes in the United States. Demographic changes may also have contributed to the improvement in survival outcomes in renal transplant recipients. In the OPTN/UNOS database, the percentage of Asian kidney recipients has increased in recent eras (3.2% in 1987 to 1994, 3. (19, 20) . Asian renal transplant recipients have a reduced prevalence of hypertension and diabetes; they are also shorter and have smaller weight, which implies a better proportionality between kidney allograft mass and body mass, which may provide a greater kidney allograft function and functional reserve.
Another possibility for death reduction in HBVϩ recipients in different eras is access to liver transplant after the kidney transplant. Of the 11 HBVϩ recipients who developed severe liver failure in our study, 9 were listed for liver transplant, 5 of whom (55.5%) underwent the procedure. Only 3 of 11 died of liver failure.
Death-censored graft survival in the HBVϩ group was not different from the HBVϪ group. In HBVϩ, kidney allograft dysfunction can be caused by recurrence of hepatitis B-related graft nephropathy in the graft or by the de novo occurrence of nephropathy. In our data, we did not identify an increased incidence of GN in HBVϩ recipients. Use of anti-viral drugs may have reduced the incidence of renal allograft nephropathy related to HBV infection.
Limitations of our study included those related to the nature of retrospective analyses. However, it is clear that the advent of potent anti-viral agents permits excellent graft and patient survival in HBV-infected recipients, although there is still an excess of liver failure compared with uninfected patients. Future prospective data are need to determine whether earlier introduction of anti-viral therapy or exclusion of potential renal transplant recipients with more histologically advanced liver disease from isolated renal transplant avoid progression to overt liver failure after renal transplant.
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